Inhibition of sphingosine kinase 1 ameliorates angiotensin ii-induced hypertension and inhibits transmembrane calcium entry via store-operated calcium channel

Molecular Endocrinology

Volumn 29, Issue 6, 2015, Pages 896-908

  Wilson, Parker C ^a   Fitzgibbon, Wayne R ^b   Garrett, Sara M ^b   Jaffa, Ayad A ^b,e   Luttrell, Louis M ^b,c   Brands, Michael W ^d   El Shewy, Hesham M ^b  

^a YALE NEW HAVEN HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CALCIUM CHANNEL; SPHINGOSINE KINASE 1; CALCIUM; LYSOPHOSPHOLIPID; PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CALCIUM CELL LEVEL; CONTROLLED STUDY; EMBRYO; GENE DELETION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPERTENSION; IMMUNOBLOTTING; MEMBRANE TRANSPORT; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE CELL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD PRESSURE; C57BL MOUSE; CELL MEMBRANE; CHRONIC DISEASE; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALIA; MUS;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CALCIUM; CALCIUM CHANNELS; CELL MEMBRANE; CHRONIC DISEASE; ENZYME ACTIVATION; GENE DELETION; HEK293 CELLS; HUMANS; HYPERTENSION; LYSOPHOSPHOLIPIDS; MALE; MICE, INBRED C57BL; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RATS, SPRAGUE-DAWLEY; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 84930846045     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1388     Document Type: Article

References (48)

1. Meyer Zu Heringdorf D, Schaefer M, Danneberg K, et al. Photolysis of intracellular caged sphingosine-1-phosphate causes Ca2+ mobilization independently of G-protein-coupled receptors. FEBS Lett. 2003;554(3):443-449.
2. Takabe K, Paugh SW, Milstien S, Spiegel S. “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60(2):181-195.
3. Olivera A, Speigel S. Sphingosine-1-phosphate as second messengerin cell proliferation induced by PDGF and FCS mitogens. Nature. 1993;365(6446):557-560.
4. Young KW, Nahorski SR. Intracellular sphingosine 1-phosphate production: a novel pathway for Ca2+ release. Semin Cell Dev Biol. 2001;12(1):19-25.
5. Venkata CR. Angiotensin receptor blockers: current status and future prospects. Am J Med. 2008;121(8):656-663.
6. Kahl CR, Means A. Regulation of cell cycle progression by calcium/ calmodulin-dependent pathways. Endocr Rev. 2003;24:719-736.
7. Tan Y, Hutchinson FM, Jaffa AA. Mechanisms of angiotensin II-induced expression of B2 kinin receptors. Am J Physiol Heart Circ Physiol. 2004;286(3):H926-H932.
8. El-Shewy HM, Al Qalam AM, Lee MH, et al. Phospholipase C and protein kinase C-/3 2 mediate insulin-like growth factor II-depen-dent sphingosine kinase 1 activation. Mol Endocrinol. 2011; 25(12):2144-2156.
9. Bielawski J, Szuic ZM, Hannun YA, Bielawska A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods. 2006;39(2):82-91.
10. Lee MH, El-Shewy HM, Luttrell DK, Luttrell LM. Role of beta-arrestin-mediated desensitization and signaling in the control of angiotensin AT1a receptor-stimulated transcription. J Biol Chem. 2008;283(4):2088-2097.
11. Usatyuk PV, Bindokas V, Gorshkova IA, et al. Photolysis of caged sphingosine-1-phosphate induces barrier enhancement and intracellular activation of lung endothelial cell signaling pathways. Am J Physiol Lung Cell Mol Physiol. 2011;300(6):L840-L850.
12. Anelli V, Gault CR, Snider AJ, Obeid LM. Role of sphingosine kinase-1 in paracrine/transcellular angiogenesis and lymphangio-genesis in vitro. FASEB. 2010;24(8):2727-2738.
13. Gratschev D, Heikkilä J, Björkbom A, et al. Sphingosine kinase as a regulator of calcium entry through autocrine sphingosine 1-phosphate signaling in thyroid FRTL-5 cells. Endocrinology. 2009; 150(11):5125-5134.
14. Parekh AB, Putney JW. Store-operated calcium channels. Physiol Rev. 2005;85(2):757-810.
15. Putney JW Jr. New molecular players in capacitative Ca2 + entry. J Cell Sci. 2007;120(Pt 12):1959-1965.
16. Pani B, Singh BB. Lipid rafts/caveolae as microdomains of calcium signaling. Cell Calcium. 2009;45(6):625-633.
17. Giachini FR, Webb RC, Tostes RC. STIM and Orai proteins: players in sexual differences in hypertension-associated vascular dysfunction? Clin Sci (Lond). 2009;118(6):391-396.
18. Côrtes SF, Lemos VR, Stoclet JC. Alterations in calcium stores in aortic myocytes from spontaneously hypertensive rats. Hypertension. 1997;29(6):1322-1328.
19. Taha TA Hannun YA, Obeid LM. Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol. 2006;39(2):113-31 Review. 2006;391(2):113-131.
20. Meyer Zu Heringdorf D. Lysophospholipid receptor-dependent and -independent calcium signaling. J Cell Biochem. 2004;92(5): 937-948.
21. Meyer Zu Heringdorf D, Lass H, Alemany R, et al. Sphingosine kinase-mediated Ca2+ signalling by G-protein-coupled receptors. EMBO J. 1998;17(10):2830-2837.
22. Itagaki K, Hengst JA, Yatani A, et al. Sphingosine 1-phosphate has dual functions in the regulation of endothelial cell permeability and Ca2+ metabolism. J Pharmacol Exp Ther. 2007;323(1):186-191.
23. Smyth JT, Huang SY, Tomita T, DeHaven WI, Mercer JC, Putney JW. Activation and regulation of store-operated calcium entry. J Cell Mol Med. 2010;14(10):2337-2349.
24. Luik RM, Wang B, Prakriya M, Wu MM, Lewis RS. Oligomeriza-tion of STIM1 couples ER calcium depletion to CRAC channel activation. Nature. 2008;454(7203):538-542.
25. Stathopulos PB, Zheng L, Li GY, Plevin MJ, Ikura M. Structural and mechanistic insights into STIM1-mediated initiation of store-operated calcium entry. Cell. 2008;135(1):110-122.
26. Zheng L, Stathopulos PB, Schindl R, Li GY, Romanin C, Ikura M. Auto-inhibitory role of the EF-SAM domain of STIM proteins in store-operated calcium entry. Proc Natl Acad Sci USA. 2006; 108(4):1337-1342.
27. Leung YM, Kwan CY. Current perspectives in the pharmacological studies of store-operated Ca2+ entry blockers. Jpn J Pharmacol. 1999;81(3):253-258.
28. Peña F, Ordaz B. Non-selective cation channel blockers: potential use in nervous system basic research and therapeutics. Mini Rev Med Chem. 2008;8(8):812-819.
29. Zou JJ, Gao YD, Geng S, Yang J. Role of STIM1/Orai1-mediated store-operated Ca2 + entry in airway smooth muscle cell proliferation. Appl Physiol. 2011;110(5):1256-1263.
30. Siow DL, Anderson CD, Berdyshev EV, Skobeleva A, Pitson SM, Wattenberg BW. Intracellular localization of sphingosine kinase 1 alters access to substrate pools but does not affect the degradative fate of sphingosine-1-phosphate. J Lipid Res. 2010;51(9):2546-2559.
31. Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. 2009;688:1-23.
32. El-Shewy HM, Johnson KR, Lee MH, Jaffa AA, Obeid LM, Luttrell LM. Insulin-like growth factors mediate heterotrimeric G protein-dependent ERK1/2 activation by transactivating sphingosine 1-phosphate receptors. J Biol Chem. 2006;281(42):31399-31407.
33. Ghosh TK, Bian J, Gill DL. Sphingosine 1-phosphate generated in the endoplasmic reticulum membrane activates release of stored calcium. J Biol Chem. 1994;269(36):22628-22635.
34. Lidington D, Schubert R, Bolz SS. Capitalizing on diversity: an integrative approach towards the multiplicity of cellular mechanisms underlying myogenic responsiveness. Cardiovasc Res. 2013; 97(3):404-412.
35. Bolz SS, Sollinger D, Derwand R, et al. Sphingosine kinase modulates microvascular tone and myogenic responses through activation of RhoA/Rho kinase. Circulation. 2003;108(3):342-347.
36. Salomone S, Soydan G, Ip PC, Hopson KM, Waeber C. Vessel-specific role of sphingosine kinase 1 in the vasoconstriction of isolated basilar arteries. Pharmacol Res. 2010;62(6):465-474.
37. Lidington D, Meissner A, Kroetsch JT, et al. The phosphorylation motif at serine 225 governs the localization and function of sphin-gosine kinase 1 in resistance arteries. Arterioscler Thromb Vasc Biol. 2009;29(11):1916–1922.
38. Tosaka M, Hashiba Y, Saito N, et al. Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: possible role in pathogenesis of cerebral vasospasm. Stroke. 2001;32(12):2913–2919.
39. Coussin F, Scott R, Wise A, Nixon GF. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ Res. 2002;91(2):151–157.
40. Salomone S PE, Tyndall S, Ip PC, Chun J, Brinkmann V, Waeber C. Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools. Br J Pharmacol. 2008;153(1):140–147.
41. Bischoff A CP, Meyer Zu Heringdorf D, Jakobs KH, Michel MC. Sphingosine-1-phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin-sensitive manner. Br J Pharmacol. 2000;130(8):1878–1883.
42. Hemmings DG XY, Davidge ST. Sphingosine 1-phosphate-induced vasoconstriction is elevated in mesenteric resistance arteries from aged female rats. Br J Pharmacol. 2004;143(2):276–284.
43. Dantas AP, Igarashi J, Michel T. Sphingosine 1-phosphate and control of vascular tone. Am J Physiol Heart Circ Physiol. 2003; 284(6):H2045–H2052.
44. Mulders AC, Hendriks-Balk MC, Mathy MJ, Michel MC, Alewi-jnse AE, Peters SL. Sphingosine kinase-dependent activation of en-dothelial nitric oxide synthase by angiotensin II. Arterioscler Thromb Vasc Biol. 2006;26(9):2043–2048.
45. Igarashi J MT. Sphingosine-1-phosphate and modulation of vascular tone. Cardiovasc Res. 2009;82(2):212–220.
46. Solomon SD, Pfeffer MA, Wittes J, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071–1080.
47. Bresalier RS, Quan H, Bolognese JA, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemopreven-tion trial. N Engl J Med. 2005;352(11):1092–1102.
48. Furuya H, Wada M, Shimizu Y, et al. Effect of sphingosine kinase 1 inhibition on blood pressure. FASEB J. 2013;27(2):656–664.